Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Depression is a risk factor for the development of Alzheimer’s disease (AD). A neurobiological and clinical continuum exists between AD and depression, with neuroinflammation and oxidative stress being involved in both diseases. Second-generation antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs), are currently investigated as neuroprotective drugs in AD. By employing a non-transgenic AD model, obtained by intracerebroventricular (i.c.v.) injection of amyloid-β (Aβ) oligomers in 2-month-old C57BL/6 mice, we recently demonstrated that the SSRI fluoxetine (FLX) and the multimodal antidepressant vortioxetine (VTX) reversed the depressive-like phenotype and memory deficits induced by Aβ oligomers rescuing the levels of transforming growth factor-β1 (TGF-β1). Aim of our study was to test FLX and VTX for their ability to prevent oxidative stress in the hippocampus of Aβ-injected mice, a brain area strongly affected in both depression and AD. The long-term intraperitoneal (i.p.) administration of FLX (10 mg/kg) or VTX (5 and 10 mg/kg) for 24 days, starting 7 days before Aβ injection, was able to prevent the over-expression of inducible nitric oxide synthase (iNOS) and NADPH oxidase 2 (Nox2) induced by Aβ oligomers. Antidepressant pre-treatment was also able to rescue the mRNA expression of glutathione peroxidase 1 (Gpx1) antioxidant enzyme. FLX and VTX also prevented Aβ-induced neurodegeneration in mixed neuronal cultures treated with Aβ oligomers. Our data represent the first evidence that the long-term treatment with the antidepressants FLX or VTX can prevent the oxidative stress phenomena related to the cognitive deficits and depressive-like phenotype observed in a non-transgenic animal model of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 3×
“When considering AD, the over-production of ROS and RNS, and then oxidative stress, has been related to increased Aβ production and/or aggregation, which in turn exacerbates neuronal oxidative damage, contributing to neuronal death in AD brain (Cheignon et al., 2018).”
BackgroundMild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Role of oxidative stress in Alzheimer’s disease
HUANG, W.-J., ZHANG, X., & CHEN, W.-W. (2016) · Biomedical Reports · doi:10.3892/br.2016.630 · Cited by 1,023
Oxidative Stress and the Pathogenesis of Alzheimer's Disease
Zhao, Y., & Zhao, B. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/316523 · Cited by 855 · cited 3×
“As previously mentioned, oxidative stress, a key factor in the progression of AD (Zhao and Zhao, 2013; Bajpai et al., 2014), reflects the imbalance between the production and quenching of reactive species in the biological system.”
BackgroundReview: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity
Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735
Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease
Marcus, D. L., Thomas, C., Rodriguez, C., Simberkoff, K., Tsai, J. S., Strafaci, J. A., & Freedman, M. L. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6750 · Cited by 513 · cited 1×
“as glutathione peroxidase 1 (Gpx1) (Marcus et al., 1998; Katrenčíková et al., 2021).”
MethodSolleiro-Villavicencio, H., & Rivas-Arancibia, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00114 · Cited by 463
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312
Activation of NADPH Oxidase in Alzheimer’s Disease Brains
Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., Hayakawa, T., Nunomura, A., Chiba, S., Perry, G., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2897 · Cited by 292
Behr, G. A., Moreira, J. C. F., & Frey, B. N. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/609421 · Cited by 205 · cited 1×
“Antidepressant drugs could also exert their therapeutic effect by suppressing the production of reactive oxygen and nitrogen species, ROS and RNS respectively, and/or rescuing the antioxidant defense (Behr et al., 2012; Wu et al., 2013).”
BackgroundBartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202 · cited 2×
“During the last decade, based on their ability to exert neuroprotection, the use of antidepressants to reduce the risk to develop AD has been proposed (Kessing et al., 2009; Kessing, 2012; Yuste et al., 2015; Bartels et al., 2018).”
BackgroundMcIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185 · cited 1×
“At clinical level, VTX has proven more effective than SSRIs in the treatment of specific clinical domains, such as cognitive deficits in elderly depressed patients (McIntyre et al., 2016; Thase et al., 2016), underlining its therapeutic potential for the treatment of cognitive impairment in depression (Bennabi et al.”
BackgroundCaraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172 · cited 6×
“…i.c.v. injection of Aβ oligomers in mice, also rescuing the levels of the synaptic proteins synaptophysin and PSD-95 as well as of TGF-β1, the deficit of which has been shown to contribute to inflammation and cognitive decline both in depression and AD (Caraci et al., 2018b; Torrisi et al., 2019).”
BackgroundInfluentialSelf-citationKessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113 · cited 1×
“During the last decade, based on their ability to exert neuroprotection, the use of antidepressants to reduce the risk to develop AD has been proposed (Kessing et al., 2009; Kessing, 2012; Yuste et al., 2015; Bartels et al., 2018).”
BackgroundMolecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75 · cited 3×
“Acute and long-term treatments with the new multimodal antidepressant vortioxetine (VTX) improve cognitive function in preclinical models of depression (Bennabi et al., 2019).”
BackgroundThe Many Faces of Mitochondrial Dysfunction in Depression: From Pathology to Treatment
Caruso, G., Benatti, C., Blom, J. M. C., Caraci, F., & Tascedda, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00995 · Cited by 65
Self-citationMehrpooya, M., Yasrebifar, F., Haghighi, M., Mohammadi, Y., & Jahangard, L. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000938 · Cited by 57 · cited 1×
“…levels of Coenzyme Q10 (CoQ10), a strong antioxidant with anti-inflammatory activity, are lower in TRD patients compared to responders depressed patients (Maes et al., 2009) and CoQ10 (200 mg/die) has been proposed as an adjuvating agent for the treatment of depression (Mehrpooya et al., 2018).”
BackgroundWang, J., Zhang, Y., Xu, H., Zhu, S., Wang, H., He, J., Zhang, H., Guo, H., Kong, J., Huang, Q., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140812114715 · Cited by 56
Cited by
Oxidative and Nitrosative stress in major depressive disorder: a case control study
Somani, A., Singh, A. K., Gupta, B., Nagarkoti, S., Dalal, P. K., & Dikshit, M. (2022) · Brain Sciences · doi:10.3390/brainsci12020144 · Cited by 54
“Indeed, conventional antidepressant medications including doxepin, fluoxetine, and vortioxetine endowed with oxidative and nitrosative scavenging activities have a protective effect [62].”
BackgroundWang, G. H.-M., Li, P., Wang, Y., Guo, J., Wilson, D. L., & Lo-Ciganic, W.-H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196342 · Cited by 23
“…venlafaxine, moclobemide, and vortioxetine), a decrease in oxidative stress (e.g., fluoxetine and vortioxetine), a decrease in β -amyloid plaques (e.g., fluoxetine, citalopram, tranylcypromine, amitriptyline, and vortioxetine), and a decrease in tau aggregation (e.g., escitalopram) [42,45–47].”
BackgroundResolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
Metadata
- Authors
- Caruso, G., Grasso, M., Fidilio, A., Torrisi, S. A., Musso, N., Geraci, F., Tropea, M. R., Privitera, A., Tascedda, F., Puzzo, D., Salomone, S., Drago, F., Leggio, G. M., & Caraci, F.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-12-24
- Volume
- 12
- Pages
- 809541-809541
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4200276375
- Cited by
- 49
- References
- 20
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.